Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis (eRapa-FAP)
Expanded Access Program for 0.5 mg eRapa in Familial Adenomatous Polyposis
調査の概要
詳細な説明
amilial adenomatous polyposis (FAP) is an inherited cancer predisposition syndrome characterized by the development of numerous colorectal adenomas and an increased risk of colorectal and other gastrointestinal malignancies. Although prophylactic surgery substantially reduces the risk of colorectal cancer, patients frequently continue to develop adenomas in the remaining gastrointestinal tract, and effective medical therapies to reduce polyp burden are limited.
Rapamycin inhibits the mammalian target of rapamycin (mTOR) signaling pathway, which regulates cell growth, proliferation, and survival. Dysregulation of mTOR signaling has been implicated in intestinal tumorigenesis associated with FAP, providing a biological rationale for mTOR inhibition as a therapeutic approach.
This expanded access program is intended to provide treatment with 0.5 mg eRapa (encapsulated rapamycin) for eligible patients with FAP when participation in a clinical trial is not feasible or available and no comparable or satisfactory therapeutic alternatives exist. Treatment decisions, dosing, duration of therapy, and clinical monitoring will be determined by the treating physician in accordance with the program inclusion and exclusion policy. Patients will undergo appropriate assessments to monitor safety, tolerability, and clinical status throughout treatment.
研究の種類
拡張アクセス タイプ
- 個々の患者
連絡先と場所
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Patient is post pubertal and reached full adult height
- Patient has FAP confirmed by APC genotype mutation tesing or a history of FAP in one of the parents. Genetic mosaics or Attenuated (as well as classical) FAP may participate
- Patient has significant colorectal and/or duodenal FAP disease burden.
Exclusion Criteria:
- Patient has existing carcinoma or high-grade dysplasia in the GI tract and/or requires imminent definitive surgical intervention (either partial or complete colectomy or duodenectomy).
- Patient with an acquired or congenital immunodeficiency, active and clinically significant tuberculosis, bacterial, fungal, or viral infections, including HIV.
- Patient has clinically significant elevations of hepatic enzymes or bilirubin, or other evidence of active hepatitis.
- Patient has clinically significant impairment of renal function.
- Patient has a history or evidence of clinically significant hyperlipoproteinemia or hypertriglyceridemia.
- Patient has active or recurrent bouts of pancreatitis, or clinically significant elevations of lipase or amylase.
- Patient is taking medications that are considered strong inducers or inhibitors of cytochrome P450 (CYP) 3A4/5 or strong inducers or inhibitors of P-glycoprotein 1 (P-gp1) that cannot be discontinued at least 1 week prior to first dose of treatment intervention and for the duration of the treatment.
- Patients with known hypersensitivity to rapamycin (sirolimus) or any of the excipients in eRapa.
- Sexually active patients who are unwilling to use a highly effective contraceptive method and to refrain from donating gametes (sperm or oocytes) throughout the time they are receiving eRAPA and for 12 weeks beyond that time, and to refrain from breast-feeding their children while on treatment.
- Patients who are pregnant or who are trying to become pregnant while taking eRapa.
- Patients unwilling or unable to undergo continued endoscopic surveillance in accordance with standards of care while taking eRapa.
- Patient has Mutations in the MUTYH gene.
研究計画
研究はどのように設計されていますか？
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。